We are a boutique health consulting firm with a focus on emerging and transformative health technologies. A view of us by the numbers:
-
>25yrs experience, including industry, consulting and leading supporting public and private think tanks
-
>500 strategic asset engagements ranging from new product planning and business formation to evidence, access and post launch commericialization
-
>250 cell & gene strategic scenarios
-
>350 precision medicine and diagnostics strategic scenarios
-
>150 medical device strategic scenarios
-
Multiple 1st in world milestones for clients where no global precedent has been established
-
Powered by a network of other solutions experts with a passion for and deep experience in transformative health technologies
Executive Leadership
Eric Faulkner
President & Chief Strategist
Eric Faulkner is a globally recognized executive in innovative technology evidence development, value demonstration, access and commercialization with >25 years of experience.
Most recently, he has served as Vice President and Exec Team Member of Value and Access at Novartis Gene Therapies, including leading the global real-world evidence function and helping scale the leading gene therapy to double blockbuster status across >40 markets. Leadership roles have included value and access, HEOR, HTA, RWE, policy and end-to-end, integrated development, launch and commercialization services for biopharma, medical device and diagnostic companies at PPD/Evidera, IQVIA, RTI Health Solutions, and the Lewin Group. In these roles he founded and lead pan-organizational Centers of Excellence in cell and gene therapy, rare disease, precision medicine, immune-oncology, medical devices and diagnostics in two of the worlds largest clinical research organizations (CROs). He has also advised US and EU governments, private equity investors, health non-profits, global think tanks, industry and medical associations on business, practical and policy implications of complex technologies.
Mr. Faulkner is a recognized global thought leader in emerging technology product access and patient/health system uptake, including >500 strategic peri- and post-approval scenarios ranging from new product planning through commercialization. Disease experience includes rare disease, oncology, neurology, cardiovascular, immunology, respiratory, infectious disease, dermatological, ocular, cognitive and other disorders.
His service includes Board, leadership, committee and special interest group work for IMAS, ARM, ARM Foundation, ASGCT, ISCT, ISPOR, Cure Rare Disease, Global Genes, the President’s Council for Advisors on Science and Technology (PCAST), Duke University’s Margolis Institute, MIT’s NewDIGs, ONCOTyrol, and others.
He serves as Assistant Professor for the Institute for Pharmacogenomics and Individualized Therapy at the University of North Carolina at Chapel Hill and as Executive Director of the Genomics Biotech and Emerging Medical Technology Institute of the National Association of Managed Care Physicians (NAMCP), a 20,000 person US managed care association of payer, provider and manufacturer executives.